Work

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.4511

Authors: Arlene O. Siefker-Radtke, Graeme Currie, Esteban Abella, Daniel A. Vaena, Arash Rezazadeh Kalebasty, Giuseppe Curigliano, Krzysztof Tupikowski, Zoran Gojko Andric, Iwona Lugowska, William Kevin Kelly

Institutions: The University of Texas MD Anderson Cancer Center, Instituto Tecnologico de Nuevo Laredo, University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, Norton Healthcare, University of Milan, European Institute of Oncology, Dolnośląskie Centrum Onkologii, The Maria Sklodowska-Curie National Research Institute of Oncology, Thomas Jefferson University, Sidney Kimmel Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947906325

Cites:

Cited by: 64

Related to: 10